ORKA.US Oruka Therapeutics, Inc.

Healthcare Biotechnology USA Stocks
99.24 USD
Close of Nov 17, 2026
25.23 115.52
Market cap
USD 6.73B
P/E
-
P/B
5.98x
ROE
-13.7%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.

Is ORKA.US undervalued?

Graham number

The Graham number of Oruka Therapeutics, Inc. cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Oruka Therapeutics, Inc. fundamental analysis

No fundamental analysis for Oruka Therapeutics, Inc. yet.

Oruka Therapeutics, Inc. stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Oruka Therapeutics, Inc.

Oruka Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing novel monoclonal antibody therapeutics for psoriasis (PsO), and other inflammatory and immunology (I&I) indications. Its lead products include ORKA-001 that targets p19 subunit of interleukin-23, which is in phase 2a trial for the treatment of PsO; and ORKA-002 that targets interleukin-17A and interleukin-17F, which is in phase 2 trial for the treatment of PsO, psoriatic arthritis, an…

Full company profile